Case report reveals successful use of sulbactam-durlobactam against CR Ab in an infant, highlighting treatment potential.
Carbapenem-resistant Acinetobacter baumannii (CR Ab ) causes severe infections and poses significant treatment challenges. Sulbactam-durlobactam (SUL-DUR) is a novel antibiotic, but its use in children and infants has not been reported. We reported the first case of an infant with acute leukemia successfully treated with SUL-DUR for CR Ab sepsis with cutaneous involvement.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: